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patients with a 
reassuring workup 
can be followed 
clinically
z Evidence summary
Prevalence and types
In areas where iodine supplementation 
is routine, the prevalence of goiter is es-
timated to be 4% to 7%; however, au-
topsy studies show a 50% prevalence of 
nodules, most of which are multinodular 
goiter.1 Multinodular goiter is diagnosed 
in up to 5% of the general population and 
can be classified as euthyroid (“nontoxic”), 
hypothyroid, or hyperthyroid (“toxic”).1 
Multinodular goiter is the most common 
diagnosis in cases of euthyroid goiter, but 
other conditions such as diffuse goiter (of-
ten idiopathic), thyroiditis, and neoplasms 
can also present in a euthyroid state. 
A patient with a euthyroid goiter;  
an opportunity to do no harm
one	of	my	patients	is	a	95-year-old	woman	
who	has	spent	most	of	the	last	95	years	
taking	very	good	care	of	herself.	she	has	
a	small,	slightly	asymmetrical	goiter	that	is	
probably	only	noticeable	to	her	and	to	me	
(when	she	regularly	calls	my	attention	to	
it).	one	of	the	precepts	of	medicine	is	to	
“first	do	no	harm,”	and	care	of	the	patient	
with	goiter	is	an	excellent	opportunity	to	
practice	this	approach.	
	 An	initial	ultrasound	can	give	you	
good	reassurance	that	the	goiter	is	benign.	
Treatment	of	a	goiter	with	thyroxine	has	
questionable	positive	value	and	puts	
the	patient	at	considerable	risk	for	the	
problems	of	hyperthyroidism	such	as	
cardiac	dysrhythmias	and	especially	
osteoporosis.	so	I	keep	tabs	on	her	
thyroid	with	a	periodic	thyroid-stimulating	
hormone	(TsH)	test	and	regular	exams,	
and	we	spend	a	few	moments	at	nearly	
every	visit	talking	about	how	the	best	
treatment	can	often	be	no	treatment	at	all.	
John P. langlois, MD
university	of	North	Carolina	school	of	Medicine,	
Chapel	Hill
A	detailed	history	and	exam,	confirmation	
of	euthyroid	status,	and	imaging	when	
appropriate	is	the	best	approach	to	
euthyroid	patients	with	thyroid	enlargement	
in	regions	where	goiters	are	not	endemic.	
ultrasound	imaging	is	recommended	
in	any	case	of	diagnostic	uncertainty.	
evaluate	dominant	or	suspicious	nodules	
further,	while	diffuse	goiters	without	
symptoms	require	no	further	evaluation	
and	can	be	followed	clinically	(strength	of	
recommendation	[sor]:	C,	expert	opinion).
	 suppressive	therapy	with	levothyroxine	
can	be	used	to	decrease	thyroid	size	for	
cosmetic	reasons	or	in	the	case	of	mild	
local	symptoms,	although	response	is	
variable	(sor:	B,	based	on	small	placebo-
controlled	trials).	Patients	with	severe	local	
symptoms	should	receive	further	evaluation	
and	possible	surgical	management.
Clinical commentary
Evidence-based answer
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Diagnosis: Exam and imaging
Studies show variable correlation be-
tween physical exam findings and find-
ings on imaging studies. In a retrospec-
tive chart review, ultrasound findings 
differed from clinical exam findings in 
63% of cases.2 Thyroid ultrasound is 
less expensive and less invasive than 
other imaging modalities, provides ex-
cellent visualization of thyroid structure 
and the nature of cysts and nodules, and 
allows for estimation of thyroid size. 
Computed tomography and mag-
netic resonance imaging perform better 
for visualization of extension of thyroid 
tissue substernally and are also preferred 
for evaluation of the neck in cases of se-
vere local complications of goiter, such 
as compressive symptoms.3 
The malignant potential in mul-
tinodular goiter (2%–4%) is similar 
to that of solitary nodules (4%–6%).3 
Therefore, any dominant nodule in a 
multinodular goiter should be evaluated 
the same way one would evaluate a soli-
tary nodule.
Treatment and follow-up
Patients with a reassuring initial work-
up can be followed clinically and should 
be assessed with serial clinical evalu-
ations. No evidence could be found 
regarding optimal intervals for exami-
nation and testing; yearly exams and 
TSH testing are considered adequate by 
some experts.4 
Because a few non-benign conditions 
such as thyroiditis and neoplasm can 
sometimes present in a euthyroid state, 
the clinician should be alert for any phys-
ical exam or laboratory changes. If any 
changes occur, then further workup is 
indicated. 
Suppressive therapy with thyrox-
ine is an option for decreasing thyroid 
size in euthyroid goiter, but this therapy 
remains controversial. One placebo- 
controlled trial of thyroid suppression 
in nontoxic multinodular goiter showed 
regression of thyroid size with suppres-
sive therapy (58% reduction in size in 
treatment group vs 5% reduction in 
control group). However, not all goiters 
responded to this therapy, and the thy-
roid size returned to pretreatment size 
within 9 months of discontinuation of 
suppressive therapy.5 
Many experts argue against the use 
of suppressive therapy in long-standing 
goiters, citing less response from these 
patients, along with concern about side 
effects and possible oversuppression, 
but the evidence in this area is limited. 
Patients who are treated with thyrox-
ine should be followed for possible side 
effects of the medication, including ar-
rhythmia and osteopenia, particularly in 
elderly patients and those who take the 
medication for long periods. 
Recommendations of others
Guidelines from the American Associa-
tion of Clinical Endocrinology’s Task 
Force on Thyroid Nodules, released in 
2006, recommends ultrasound be used 
routinely in the case of multinodular 
goiter to assist with diagnosis, detect 
suspicious nodules that may require 
biopsy, and to serve as an objective base-
line measure. This group recommends 
against use of suppression therapy in 
long-standing goiters.6   n
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